EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, MindBio Therapeutics's enterprise value is C$5.26 Mil.
MindBio Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was C$-0.57 Mil. Therefore, MindBio Therapeutics's EV-to-Revenue for today is -9.16.
The historical rank and industry rank for MindBio Therapeutics's EV-to-Revenue or its related term are showing as below:
XCNQ:MBIO'
s EV-to-Revenue Range Over the Past 10 Years
Min: -42.15 Med: 14.64 Max: 77.09
Current: -9.16
During the past 4 years, the highest EV-to-Revenue of MindBio Therapeutics was 77.09. The lowest was -42.15. And the median was 14.64.
XCNQ:MBIO's EV-to-Revenue is ranked worse than 100% of 997
companies
in the Biotechnology industry
Industry Median: 7.39
vs XCNQ:MBIO: -9.16
MindBio Therapeutics EV-to-Revenue Historical Data
The historical data trend for MindBio Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MindBio Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, MindBio Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindBio Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where MindBio Therapeutics's EV-to-Revenue falls into.
MindBio Therapeutics's current Enterprise Value is C$5.26 Mil.
MindBio Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindBio Therapeutics's share price for today is C$0.005.
MindBio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindBio Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of MindBio Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough micro dosing studies. Geographically, the company's activities take place in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XCNQ:MBIO has been successfully added to your 